<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - RITUXIMAB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>RITUXIMAB</h1>

        <p><a href="../drugClass/PHP34582.html">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them (in combination with methotrexate)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g, then 1 g after 2 weeks, patients should receive premedication before each infusion (consult product literature for details).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of previously untreated stage III&#8211;IV follicular lymphoma (in combination with other chemotherapy)</span>,
                <span class="indication">Maintenance therapy in patients with follicular non-Hodgkin's lymphoma that has responded to induction therapy (in combination with other chemotherapy)</span>,
                <span class="indication">Treatment of diffuse large B-cell non-Hodgkin's lymphoma (in combination with other chemotherapy)</span>,
                <span class="indication">Treatment of chemotherapy-resistant or relapsed stage III&#8211;IV follicular non-Hodgkin's lymphoma</span>,
                <span class="indication">Previously untreated or relapsed chronic lymphocytic leukaemia</span>,
                <span class="indication">Induction of remission in patients with severe, active granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis (in combination with glucocorticoids)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Patients should receive premedication before each dose (consult product literature for details) (consult product literature or local protocols).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletion in fetus.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Severe heart failure (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)</li>
            <li>severe infection</li>
            <li>severe, uncontrolled heart disease (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Abdominal pain, anaemia, antibody formation, aplastic anaemia, arthralgia, asthenia, blood disorders, depression, dyspepsia, headache, hypertension, hypotension, injection-site reactions, leucopenia, lupus erythematosus-like syndrome, migraine, muscle spasm, pancytopenia, paraesthesia, progressive multifocal leucoencephalopathy, pruritus, rhinitis, severe fatal skin reactions, severe skin reactions (permanently discontinue treatment if occurs), sore throat, Stevens-Johnson syndrome (permanently discontinue treatment if occurs), thrombocytopenia, toxic epidermal necrolysis (permanently discontinue treatment if occurs), urticaria, worsening heart failure,
              </p>
        
        
            <section class="advice">
                <h3>Progressive multifocal leucoencephalopathy</h3>
              <p>Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.</p>
            </section>
            <section class="advice">
              <p>For full details, including management of side-effects, consult product literature.</p>
            </section>
            <section class="advice">
              <p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous infusion</i> (<i>MabThera</i>
            <tm tmtype="reg"/>), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to 1-4&#8239;mg/mL and gently invert bag to avoid foaming.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
                <h3>Alert card</h3>
              <p>Patients treated for granulomatosis with polyangiitis and microscopic polyangiitis or rheumatoid arthritis should be provided with a patient alert card with each infusion.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA65</h3>
              <p outputclass="title">Rituximab for aggressive non-Hodgkin&#8217;s lymphoma (September 2003)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV.</p> <p>The use of rituximab for localised (stage I) disease should be limited to clinical trials.</p><xref format="html" href="http://www.nice.org.uk/TA65">www.nice.org.uk/TA65</xref>
                <a href="http://www.nice.org.uk/TA65" target="_blank">www.nice.org.uk/TA65</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA137</h3>
              <p outputclass="title">Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma (February 2008)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with chemotherapy, is an option for the induction of remission in patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma.</p> <p>Rituximab monotherapy as maintenance therapy is an option for the treatment of patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma in remission induced with chemotherapy (with or without rituximab).</p> <p>Rituximab monotherapy is an option for the treatment of patients with relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).</p><xref format="html" href="http://www.nice.org.uk/TA137">www.nice.org.uk/TA137</xref>
                <a href="http://www.nice.org.uk/TA137" target="_blank">www.nice.org.uk/TA137</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA174</h3>
              <p outputclass="title">Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.</p><xref format="html" href="http://www.nice.org.uk/TA174">www.nice.org.uk/TA174</xref>
                <a href="http://www.nice.org.uk/TA174" target="_blank">www.nice.org.uk/TA174</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA193</h3>
              <p outputclass="title">Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition:</p> <ul> <li>is refractory to fludarabine (that is, it has not responded to fludarabine, or has relapsed within 6 months of treatment), <b>or</b> </li> <li>has previously been treated with rituximab, unless it was in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or with chemotherapy other than fludarabine and cyclophosphamide.</li> </ul> <p>Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for patients with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with rituximab, unless rituximab has been given as specified above.</p><xref format="html" href="http://www.nice.org.uk/TA193">www.nice.org.uk/TA193</xref>
                <a href="http://www.nice.org.uk/TA193" target="_blank">www.nice.org.uk/TA193</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA195</h3>
              <p outputclass="title">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</p> <p>Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.</p><xref format="html" href="http://www.nice.org.uk/TA195">www.nice.org.uk/TA195</xref>
                <a href="http://www.nice.org.uk/TA195" target="_blank">www.nice.org.uk/TA195</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA226</h3>
              <p outputclass="title">Rituximab for the first-line maintenance treatment of follicular non-Hodgkin&#8217;s lymphoma (June 2011)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkins&#8217;s lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.</p><xref format="html" href="http://www.nice.org.uk/TA226">www.nice.org.uk/TA226</xref>
                <a href="http://www.nice.org.uk/TA226" target="_blank">www.nice.org.uk/TA226</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA243</h3>
              <p outputclass="title">Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with:</p> <ul> <li>cyclophosphamide, vincristine and prednisolone (CVP);</li> <li>cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP);</li> <li>mitoxantrone, chlorambucil and prednisolone (MCP);</li> <li>cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alfa (CHVPi); <i>or</i> </li> <li>chlorambucil</li> </ul> <p>is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.</p><xref format="html" href="http://www.nice.org.uk/TA243">www.nice.org.uk/TA243</xref>
                <a href="http://www.nice.org.uk/TA243" target="_blank">www.nice.org.uk/TA243</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA308</h3>
              <p outputclass="title">Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:</p> <ul> <li>further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose, <b>or</b> </li> <li>cyclophosphamide is contraindicated or not tolerated, <b>or</b> </li> <li>the patient has not completed their family, and treatment with cyclophosphamide may materially affect their fertility, <b>or</b> </li> <li>the disease has remained active or progressed despite a course of cyclophosphamide lasting 3&#8211;6 months <b>or</b> </li> <li>the patient has had uroepithelial malignancy.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA308">www.nice.org.uk/TA308</xref>
                <a href="http://www.nice.org.uk/TA308" target="_blank">www.nice.org.uk/TA308</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            History of cardiovascular disease; in adults exacerbation of angina, arrhythmia, and heart failure have been reported
          </li>
          <li>
            patients receiving cardiotoxic chemotherapy; in adults exacerbation of angina, arrhythmia, and heart failure have been reported
          </li>
          <li>
            transient hypotension occurs frequently during infusion (anti-hypertensives may need to be withheld for 12 hours before infusion)
          </li>
        </ul>
        <ul>
          <li>
              <strong>When used for rheumatoid arthritis:</strong>
            predisposition to infection
          </li>
        </ul>
        <ul>
          <li>
            <p>Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking <b>rituximab</b>. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>
          </li>
          <li>
            <p>For full details on cautions, consult product literature or local treatment protocol.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Effective contraception (in both sexes) required during and for 12 months after treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>For full details on monitoring requirements consult product literature.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of RITUXIMAB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP101337"><a href="../medicinalForm/PHP101337.html" data-target="#PHP101337" data-action="load">Solution for injection</a></div>
            <div id="PHP75274"><a href="../medicinalForm/PHP75274.html" data-target="#PHP75274" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
